In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you'll be hearing from Ksenija Pavletic, partner and chief commercial officer at Jeito Capital and Thierry Laugel, managing partner at Kurma Partners. We dive into France’s biotech ecosystem and what still needs to happen for more early innovation to translate into investable, scalable biotech.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsKsenija Pavletic, Partner and Chief Commercial Officer, Jeito CapitalThierry Laugel, Managing Partner, Kurma PartnersDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from BioSpace
Rethinking hair loss treatment
ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck
Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds
Inside Germany’s biotech capital infrastructure and innovation engine
Get summaries like this every morning.
Free AI-powered recaps of BioSpace and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.